HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Warnke, R. A. Articles by Weissman, I. L. Search for Related Content PubMed Articles by Warnke, R. A. Articles by Weissman, I. L.

The Pathology and Homing of a Transplantable Murine B Cell Leukemia (BCL₁)¹

Laboratory for Experimental Oncology, Department of Pathology, and the Division of Immunology, Department of Medicine, Stanford University School of Medicine, Stanford, California 94305

Abstract

The pathology and homing characteristics of a murine B cell leukemia are described. Experiments utilizing autoradiography to determine the early homing pattern of the leukemic cells revealed a pronounced localization of the labeled cells to the spleen. The cells that were seen in the white pulp showed preferential localization to the follicles or B cell domains. Tissue section immunofluorescence with antibodies to - and -light chains was used to study the initial mouse with this disease as well as to study the mice that were injected with in vivo passaged cells. These mice also showed predominant involvement of the spleen. Although the initial mouse with this disease had 200,000 -bearing B lymphocytes per mm³ in the peripheral blood and closely resembled a human chronic lymphocytic leukemia patient, the studies described suggest that this murine B cell neoplasm is a lymphoma with a striking predilection for splenic involvement. The other organs including the bone marrow as well as the peripheral blood appeared to be involved secondarily. This unusual spontaneously occurring murine B cell disease provides a useful model for the investigation of certain commonly occurring human lymphomas and leukemias.

Footnotes

¹ This work was supported by National Institutes of Health Grants AI 10293 and 11313.

² Department of Medicine A, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.

³ Fellow of the Leukemia Society of America.

⁴ Recipient of Pathology Training Grant GM-12236 from the National Institutes of Health.

⁵ Investigator, Howard Hughes Medical Institute.

⁶ Faculty Research Awardee, American Cancer Society.

This article has been cited by other articles:

				A. B. Pillai, T. I. George, S. Dutt, P. Teo, and S. Strober Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation J. Immunol., May 15, 2007; 178(10): 6242 - 6251. [Abstract] [Full Text] [PDF]

				M. Edinger, Y.-A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging Blood, January 15, 2003; 101(2): 640 - 648. [Abstract] [Full Text] [PDF]

				J. M. Timmerman, C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas Blood, March 1, 2001; 97(5): 1370 - 1377. [Abstract] [Full Text] [PDF]

				B. Kotzin and S Strober Role of the spleen in the growth of a murine B cell leukemia Science, April 4, 1980; 208(4439): 59 - 61. [Abstract] [PDF]